Sanofi Advances Kymera's Next-Generation IRAK4 Degrader KT-485 to Clinical Testing
核心洞察
Sanofi has selected Kymera's KT-485 (搜索), a next-generation oral IRAK4 (搜索) degrader, to advance into Phase 1 clinical testing next year for immuno-inflammatory diseases (搜索).
KT-485 (搜索) demonstrated superior preclinical performance compared to KT-474, showing increased selectivity and potency with a favorable safety profile.
The collaboration positions Kymera to receive up to $975 million in potential milestones, with the company already achieving a $20 million milestone in Q2 2025.
Sanofi has informed Kymera Therapeutics (搜索) that it will advance KT-485 (搜索)/SAR447971 (搜索), a first-in-class oral IRAK4 (搜索) degrader, into clinical studies while discontinuing development of KT-474. The decision reflects KT-485's compelling preclinical profile and marks a significant milestone in the companies' collaboration to develop targeted protein degradation therapies for immunological diseases (搜索).
Superior Preclinical Performance Drives Selection
KT-485 (搜索) demonstrated an improved target product profile compared to KT-474 in preclinical testing, showing greater potency and selectivity along with a generally improved overall profile. The next-generation IRAK4 (搜索) degrader is expected to advance into Phase 1 testing next year following extensive preclinical work supporting its robust development potential.
"In preclinical testing, KT-485 (搜索) demonstrated an improved target product profile as compared to KT-474. With greater potency and selectivity and a generally improved overall profile, KT-485 is best-positioned to capitalize on the significant potential of IRAK4 (搜索) degradation," commented Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics (搜索).
Novel Mechanism Targets Multiple Immune Functions
KT-485 (搜索) represents a first-in-class approach to treating immuno-inflammatory diseases (搜索) through targeted degradation of IRAK4 (搜索), a master regulator of innate immunity and key protein of the myddosome complex. IRAK4 mediates signaling through IL-1 and toll-like receptors, functioning as a scaffolding kinase at the interface of innate and adaptive immune responses.
Unlike conventional small molecule inhibitors, IRAK4 (搜索) degradation eliminates the protein completely, impacting both kinase and scaffolding functions. This comprehensive approach has the potential to achieve broad, well-tolerated anti-inflammatory effects, providing a novel therapeutic strategy for various immune-inflammatory diseases.
Substantial Financial Milestones and Partnership Terms
Under the collaboration agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485 (搜索). The company is eligible to receive up to $975 million in potential clinical, regulatory and commercial milestones, including an additional milestone upon the start of Phase 1 clinical testing.
Sanofi has exercised its participation election right for the IRAK4 (搜索) target, and Kymera may opt-in to a 50/50 development and profit share of KT-485 (搜索) in the United States. The collaboration also includes double-digit royalties for Kymera.
Strategic Focus on Transforming Immunology Treatment
The partnership between Sanofi and Kymera reflects both companies' commitment to targeting the IRAK4 (搜索) pathway with degraders that are functionally differentiated from small molecule inhibitors. Sanofi is collaborating with Kymera on IRAK4 degrader development outside of oncology and immuno-oncology fields.
"Sanofi's intention to advance KT-485 (搜索) into clinical testing and to direct all collaboration resources to the next-generation IRAK4 (搜索) degrader is a reflection of the molecule's compelling preclinical profile and of Sanofi's and Kymera's commitment to transform immunology treatment paradigms," Mainolfi stated.
Clinical data generated to date demonstrates the potential of IRAK4 (搜索) degradation to deliver the combined activity of upstream biologics in an oral drug format for multiple diseases, representing a significant advancement in convenience and accessibility for patients with immunological conditions.